News

Company News: Prof. Cornelis Melief to Present Novel AMPLIVANT™ Platform at AACR Annual Meeting 2013

ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced that Prof. Cornelis Melief, M.D., will present details on the novel AMPLIVANTTM platform at this year’s American Association for Cancer Research (AACR) Annual Meeting. AMPLIVANTTM is based on a powerful, proprietary toll-like receptor (TLR) ligand improving immunotherapies.

 

Presentation title: “Synthetic vaccine for immunotherapy of high risk HPV infections“

Symposium: SY27 “New Cancer Vaccines“

Abstract number: SY27-01

Date: April 9, 2013, at 10:40 a.m.

Location: Room 202 at the Washington Convention Center.

 

The abstract is available at the AACR website www.aacr.org.